Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.

Journal of cancer research and clinical oncology - 1 Jun 2020

Chan Carmen W H, Law Bernard M H, So Winnie K W, Chow Ka Ming, Waye Mary M Y

Abstract excerpt

PURPOSE: To review recent pharmacogenomics studies on breast cancer patients undergoing tamoxifen therapy, highlighting how our knowledge on cytochrome P450 2D6 (CYP2D6) can help to guide the development of adjuvant therapies for these patients. METHODS: A comprehensive literature search was conducted. Articles reporting findings pertaining to the effect of CYP2D6 on the therapeutic efficacy of tamoxifen, those...

Topics

Join the communities discussing this publication.

Antineoplastic Agents, Hormonal
Breast Neoplasms
Cytochrome P-450 CYP2D6
Pharmacogenetics
Polymorphism, Single Nucleotide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Treatment Outcome

Source

Identifiers

PMID: 32270286
DOI: 10.1007/s00432-020-03206-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.PMID 32270286Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.Semantic proximity Read ↗

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.Semantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Pharmacogenetics of endocrine therapy for breast cancer.Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

CYP2D6 pharmacogenomics of tamoxifen treatment.Semantic proximity Read ↗

CYP2D6 pharmacogenomics of tamoxifen treatment.Semantic proximity Read ↗

Understanding CYP2D6 and its role in tamoxifen metabolism.Semantic proximity Read ↗

CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical RelevanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.